他汀类药物与肝毒性：关注脂肪肝患者 - Suppr

Suppr

超能文献

Statins and hepatotoxicity: focus on patients with fatty liver.

作者信息

Chalasani Naga

机构信息

Indiana University School of Medicine, Indianopolis, IN 46202, USA.

出版信息

Hepatology. 2005 Apr;41(4):690-5. doi: 10.1002/hep.20671.

DOI:10.1002/hep.20671

PMID:15789367

Abstract

摘要

相似文献

Statins and hepatotoxicity: focus on patients with fatty liver.

Hepatology. 2005 Apr;41(4):690-5. doi: 10.1002/hep.20671.

Prescribing statins to patients with nonalcoholic fatty liver disease: real cardiovascular benefits outweigh theoretical hepatotoxic risk.

Cardiovasc Ther. 2009 Fall;27(3):216-20. doi: 10.1111/j.1755-5922.2009.00088.x. Epub 2009 Jun 23.

Safety of statins: effects on muscle and the liver.

Cleve Clin J Med. 2005 Nov;72(11):990-3, 996-1001. doi: 10.3949/ccjm.72.11.990.

[Statins in chronic liver diseases: safety and effect].

Zhonghua Gan Zang Bing Za Zhi. 2010 Jun;18(6):478-80. doi: 10.3760/cma.j.issn.1007-3418.2010.06.022.

Means and ends of statins and low-density lipoprotein cholesterol lowering.

J Am Coll Cardiol. 2007 Jul 31;50(5):419-20. doi: 10.1016/j.jacc.2007.04.044. Epub 2007 Jul 16.

Stopping statins.

Circulation. 2004 Oct 19;110(16):2280-2. doi: 10.1161/01.CIR.0000145140.06171.3D.

Statins in liver disease: a molehill, an iceberg, or neither?

Hepatology. 2008 Aug;48(2):662-9. doi: 10.1002/hep.22402.

Liver tests are irrelevant when prescribing statins.

Lancet. 2010 Dec 4;376(9756):1882-3. doi: 10.1016/S0140-6736(10)62142-3. Epub 2010 Nov 23.

Are statins safe?

Geriatr Nurs. 2007 Jul-Aug;28(4):212-7. doi: 10.1016/j.gerinurse.2007.06.005.

Statins for hyperlipidemia in patients with chronic liver disease: are they safe?

Clin Gastroenterol Hepatol. 2006 Jul;4(7):838-9. doi: 10.1016/j.cgh.2006.04.020.

引用本文的文献

Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis.

Front Cardiovasc Med. 2025 Feb 5;11:1415668. doi: 10.3389/fcvm.2024.1415668. eCollection 2024.

KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025.

Clin Mol Hepatol. 2025 Feb;31(Suppl):S1-S31. doi: 10.3350/cmh.2025.0045. Epub 2025 Feb 19.

Management of dyslipidaemia in patients with comorbidities-facing the challenge.

Eur Heart J Cardiovasc Pharmacother. 2025 Mar 13;11(2):164-173. doi: 10.1093/ehjcvp/pvae095.

Lipid-Lowering Medications for Managing Dyslipidemia: A Narrative Review.

Cureus. 2024 Jul 23;16(7):e65202. doi: 10.7759/cureus.65202. eCollection 2024 Jul.

Genetically mimicked effects of ASGR1 inhibitors on all-cause mortality and health outcomes: a drug-target Mendelian randomization study and a phenome-wide association study.

BMC Med. 2023 Jul 3;21(1):235. doi: 10.1186/s12916-023-02903-w.

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Signal Transduct Target Ther. 2022 Aug 13;7(1):287. doi: 10.1038/s41392-022-01119-3.

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.

Clin Mol Hepatol. 2021 Jul;27(3):363-401. doi: 10.3350/cmh.2021.0178. Epub 2021 Jun 22.

Intravenous Curcumin Mitigates Atherosclerosis Progression in Cholesterol-Fed Rabbits.

Adv Exp Med Biol. 2021;1308:45-54. doi: 10.1007/978-3-030-64872-5_5.

Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management.

Curr Hepatol Rep. 2020 Sep;19(3):315-326. doi: 10.1007/s11901-020-00530-0. Epub 2020 Jun 29.

Choosing statins: a review to guide clinical practice.

Arch Endocrinol Metab. 2021 Nov 1;64(6):639-653. doi: 10.20945/2359-3997000000306. Epub 2020 Nov 9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Statins and hepatotoxicity: focus on patients with fatty liver.

Hepatology. 2005 Apr;41(4):690-5. doi: 10.1002/hep.20671.

Prescribing statins to patients with nonalcoholic fatty liver disease: real cardiovascular benefits outweigh theoretical hepatotoxic risk.

Cardiovasc Ther. 2009 Fall;27(3):216-20. doi: 10.1111/j.1755-5922.2009.00088.x. Epub 2009 Jun 23.

Safety of statins: effects on muscle and the liver.

Cleve Clin J Med. 2005 Nov;72(11):990-3, 996-1001. doi: 10.3949/ccjm.72.11.990.

[Statins in chronic liver diseases: safety and effect].

Zhonghua Gan Zang Bing Za Zhi. 2010 Jun;18(6):478-80. doi: 10.3760/cma.j.issn.1007-3418.2010.06.022.

Means and ends of statins and low-density lipoprotein cholesterol lowering.

J Am Coll Cardiol. 2007 Jul 31;50(5):419-20. doi: 10.1016/j.jacc.2007.04.044. Epub 2007 Jul 16.

Stopping statins.

Circulation. 2004 Oct 19;110(16):2280-2. doi: 10.1161/01.CIR.0000145140.06171.3D.

Statins in liver disease: a molehill, an iceberg, or neither?

Hepatology. 2008 Aug;48(2):662-9. doi: 10.1002/hep.22402.

Liver tests are irrelevant when prescribing statins.

Lancet. 2010 Dec 4;376(9756):1882-3. doi: 10.1016/S0140-6736(10)62142-3. Epub 2010 Nov 23.

Are statins safe?

Geriatr Nurs. 2007 Jul-Aug;28(4):212-7. doi: 10.1016/j.gerinurse.2007.06.005.

Statins for hyperlipidemia in patients with chronic liver disease: are they safe?

Clin Gastroenterol Hepatol. 2006 Jul;4(7):838-9. doi: 10.1016/j.cgh.2006.04.020.

引用本文的文献

Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis.

Front Cardiovasc Med. 2025 Feb 5;11:1415668. doi: 10.3389/fcvm.2024.1415668. eCollection 2024.

KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025.

Clin Mol Hepatol. 2025 Feb;31(Suppl):S1-S31. doi: 10.3350/cmh.2025.0045. Epub 2025 Feb 19.

Management of dyslipidaemia in patients with comorbidities-facing the challenge.

Eur Heart J Cardiovasc Pharmacother. 2025 Mar 13;11(2):164-173. doi: 10.1093/ehjcvp/pvae095.

Lipid-Lowering Medications for Managing Dyslipidemia: A Narrative Review.

Cureus. 2024 Jul 23;16(7):e65202. doi: 10.7759/cureus.65202. eCollection 2024 Jul.

Genetically mimicked effects of ASGR1 inhibitors on all-cause mortality and health outcomes: a drug-target Mendelian randomization study and a phenome-wide association study.

BMC Med. 2023 Jul 3;21(1):235. doi: 10.1186/s12916-023-02903-w.

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Signal Transduct Target Ther. 2022 Aug 13;7(1):287. doi: 10.1038/s41392-022-01119-3.

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease.

Clin Mol Hepatol. 2021 Jul;27(3):363-401. doi: 10.3350/cmh.2021.0178. Epub 2021 Jun 22.

Intravenous Curcumin Mitigates Atherosclerosis Progression in Cholesterol-Fed Rabbits.

Adv Exp Med Biol. 2021;1308:45-54. doi: 10.1007/978-3-030-64872-5_5.

Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management.

Curr Hepatol Rep. 2020 Sep;19(3):315-326. doi: 10.1007/s11901-020-00530-0. Epub 2020 Jun 29.

Choosing statins: a review to guide clinical practice.

Arch Endocrinol Metab. 2021 Nov 1;64(6):639-653. doi: 10.20945/2359-3997000000306. Epub 2020 Nov 9.